US Patent 11,633,369: Scope, Claims, Exclusivity, and Epidiolex Patent Landscape
US Patent No. 11,633,369 protects specific cannabidiol seizure-treatment regimens and an oral CBD formulation with a nominal 100 mg/mL CBD concentration, sesame oil, ethanol, and flavoring or sweetener. The claims are directed to Epidiolex-type products and dosing protocols for Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex, and Doose syndrome. The patent creates both method-of-use and formulation barriers, but its enforceability depends on proving the claimed impurity profile, concentration, dosing escalation, and disease indication.
What does US Patent 11,633,369 protect?
The patent has two principal claim groups:
| Claim group |
Claims |
Protected subject matter |
| Treatment methods |
1-28 |
Oral CBD treatment for specified epilepsy syndromes using approximately 5 mg/kg/day initially, followed by approximately 5 mg/kg/day dose increases up to approximately 25 mg/kg/day |
| Oral formulation |
29-32 |
CBD formulation containing sesame oil, ethanol, flavoring or sweetener, and approximately 90-110 mg/mL CBD |
The claims combine product and clinical-use limitations. A competing product must satisfy the relevant formulation limitations and, for method claims, must be administered according to the specified dosing and disease conditions.
The patent is particularly relevant to Epidiolex, an FDA-approved oral cannabidiol solution marketed by Jazz Pharmaceuticals through its GW Pharmaceuticals business. FDA approved Epidiolex in 2018 for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, and expanded the indication to seizures associated with tuberous sclerosis complex in 2020.[1,2]
What are the key limitations in claim 1?
Claim 1 requires all of the following:
- Treatment of a patient with Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex, or Doose syndrome.
- Oral administration.
- A pharmaceutical formulation containing CBD.
- CBD concentration of approximately 100 mg/mL.
- A CBD drug substance containing at least one specified impurity limitation:
- CBDV at not more than 1.0% w/w;
- Δ9-THC at not more than 0.15% w/w; or
- CBD-C4 at not more than 0.5% w/w.
- An initial CBD dose of approximately 5 mg/kg/day.
- Gradual escalation by approximately 5 mg/kg/day increments.
- A maximum dose of approximately 25 mg/kg/day.
The "at least one" language in claim 1 creates an alternative limitation. A formulation may fall within the claim if it satisfies any one of the three impurity thresholds, assuming the remaining limitations are met.
Claims 2 and 3 narrow the impurity profile:
- Claim 2 requires at least two of the three specified impurity limitations.
- Claim 3 requires all three.
- Claim 4 adds a CBDA limit of not more than 0.15% w/w.
Claims 5 and 12-28 create disease-specific and dose-specific subcombinations.
How do the dependent treatment claims narrow the patent scope?
The dependent claims divide the treatment estate into clinical outcomes, seizure types, diseases, and dose ranges.
| Claim feature |
Relevant claims |
Practical effect |
| At least 50% seizure reduction |
6-8, 14, 18, 22, 27 |
Requires a clinical outcome compared with a pre-treatment baseline |
| Specified seizure types |
9-11, 15, 19, 23, 28 |
Limits coverage to atonic, tonic, clonic, tonic-clonic, absence, or myoclonic seizures |
| Lennox-Gastaut syndrome |
12-15 |
Narrows the patient population and permits a 10-20 mg/kg/day target range |
| Dravet syndrome |
16-19 |
Narrows the patient population and permits a 10-20 mg/kg/day target range |
| Tuberous sclerosis complex |
20-23 |
Requires escalation to approximately 25 mg/kg/day |
| Doose syndrome |
24-28 |
Covers escalation from approximately 10 mg/kg/day to approximately 25 mg/kg/day |
The 50% seizure-reduction limitations may be difficult to apply prospectively because infringement analysis would require evidence of baseline seizure frequency and post-treatment seizure frequency. Those limitations can also create proof issues in clinical practice where seizure diaries are incomplete or the patient receives multiple antiseizure medicines.
What formulation is protected by claims 29-32?
Claim 29 covers an oral formulation containing:
- CBD drug substance;
- Sesame oil;
- Ethanol;
- Flavoring, sweetener, or both;
- CBD at approximately 90-110 mg/mL; and
- At least one of the three specified impurity limits.
Claim 30 requires both flavoring and sweetener. Claim 31 narrows the ethanol concentration to approximately 71.1-86.9 mg/mL. Claim 32 requires:
- Sweetener at approximately 0.45-0.55 mg/mL; and
- Flavoring at approximately 0.18-0.22 mg/mL.
These claims are directed to a narrow oral solution architecture rather than CBD generally. A formulation using a different carrier oil, no ethanol, a materially different CBD concentration, or a different excipient system may avoid literal infringement of claims 29-32, although other patents or the doctrine of equivalents could remain relevant.
The formulation claims also require the CBD drug substance to meet at least one impurity threshold. The concentration limits apply to the formulation, while the impurity limits are measured by weight relative to the CBD drug substance. This distinction matters for analytical testing and claim construction.
What is the patent expiration date for US 11,633,369?
The patent issued on April 25, 2023. Its nominal statutory expiration is June 30, 2037, based on the earliest claimed priority date of June 30, 2017, subject to any applicable patent-term adjustment or correction recorded by the USPTO.[3]
The patent term should be assessed together with any terminal disclaimer, patent-term adjustment, patent-term extension, and related Orange Book listing. A patent’s expiration date does not by itself determine the earliest lawful generic launch date because FDA exclusivity and other listed patents may expire on different dates.
What is the Orange Book status of Epidiolex?
Epidiolex is an FDA-approved small-molecule drug, not a biologic. Generic competition proceeds through the ANDA pathway rather than the biosimilar pathway.
| Regulatory event |
Date or status |
| Initial FDA approval |
June 25, 2018 |
| Initial indications |
Lennox-Gastaut syndrome and Dravet syndrome |
| Tuberous sclerosis complex indication |
Approved August 2020 |
| Dosage form |
Oral solution |
| CBD concentration |
100 mg/mL |
| FDA exclusivity |
NCE and orphan-drug exclusivity periods applied at different stages |
| Regulatory pathway for generics |
ANDA under section 505(j) |
| Biosimilar pathway |
Not applicable |
FDA’s labeling identifies Epidiolex as a 100 mg/mL oral solution containing cannabidiol, sesame seed oil, dehydrated alcohol, strawberry flavor, and sucralose.[1] The label recommends a starting dosage of 2.5 mg/kg twice daily, equivalent to 5 mg/kg/day, with escalation to 10 mg/kg twice daily for most approved indications. For tuberous sclerosis complex, the recommended maintenance dosage is 12.5 mg/kg twice daily, equivalent to 25 mg/kg/day.[1]
The patent claims track these dosing parameters closely. A generic applicant could therefore face both patent and regulatory scrutiny if its proposed labeling reproduces the same dosing instructions for the same indications.
When does Epidiolex lose exclusivity?
Epidiolex’s exclusivity has multiple components:
- New chemical entity exclusivity initially blocked ANDA approval for five years from FDA approval, subject to statutory exceptions.
- Orphan-drug exclusivity applied to the approved rare-disease indications for seven years from the relevant approval.
- Patent protection extends beyond the original NCE period, including the patent at issue and potentially related listed patents.
For the original 2018 approval, five-year NCE exclusivity generally reached June 25, 2023. The original orphan designation periods generally extended into 2025 for the LGS and Dravet indications. The TSC indication received separate regulatory treatment and may have its own orphan-exclusivity analysis.
A generic sponsor can file an ANDA before patent expiration and submit a Paragraph IV certification challenging listed patents. FDA approval may still be delayed by the statutory 30-month stay if the patent holder timely files infringement litigation.
How strong is the patent estate for CBD epilepsy treatment?
The estate is strongest against a product that copies the complete Epidiolex profile:
- 100 mg/mL CBD;
- Sesame oil and ethanol;
- Strawberry-type flavoring and sweetener;
- Low Δ9-THC and other cannabinoid impurities;
- FDA labeling for LGS, Dravet syndrome, or TSC;
- Starting dosage of 5 mg/kg/day;
- Dose escalation to 20 or 25 mg/kg/day.
The estate is weaker against products that materially change one or more claim elements. Potential design-around vectors include:
- A CBD concentration outside the approximately 90-110 mg/mL range.
- A non-sesame carrier oil.
- An ethanol-free or materially different solvent system.
- A formulation using a purified synthetic CBD substance with a different impurity profile.
- Labeling that omits a patented indication, subject to induced-infringement risk.
- A dosing regimen that does not use the claimed starting dose or escalation pattern.
- A product administered through a non-oral route.
The most important technical barrier is the drug-substance definition. A competitor must characterize CBDV, Δ9-THC, CBD-C4, and CBDA at the claimed thresholds. Batch-to-batch variation, analytical methods, detection limits, and the meaning of "based on the weight of the drug substance" could become central in litigation.
What Paragraph IV challenges and litigation affect the patent?
The principal entry risk comes from ANDA applicants seeking approval for a generic cannabidiol oral solution. A Paragraph IV challenge would likely target one or more listed patents covering:
- CBD treatment of LGS and Dravet syndrome;
- CBD treatment of TSC;
- The 100 mg/mL oral solution;
- Excipients and impurity specifications;
- Dose-escalation instructions.
A patent holder may sue within 45 days after receiving a Paragraph IV notice. The resulting litigation can trigger a 30-month FDA approval stay under 21 U.S.C. § 355(j)(5)(B)(iii).
The supplied claim set does not establish whether a particular generic company has filed a Paragraph IV certification, whether a notice letter was served, or whether a settlement agreement exists. Those facts must be tied to an Orange Book entry, ANDA litigation docket, or SEC disclosure before being treated as established. The patent claims alone do not prove litigation, settlement, or commercial launch timing.
Are biosimilars a risk to Epidiolex?
No. Epidiolex contains the small molecule cannabidiol and is regulated as a conventional drug. Competitors would generally use the ANDA pathway and demonstrate pharmaceutical equivalence and bioequivalence. The relevant competitors are generic CBD oral-solution manufacturers, not biosimilar sponsors.
An ANDA applicant may attempt to avoid method-of-use liability through a section viii statement that omits patented indications from its labeling. That strategy is less effective if the proposed labeling still encourages the patented use or if the formulation claims are infringed independently of the label.
How does US 11,633,369 compare with ordinary CBD patents?
US 11,633,369 is narrower than a patent claiming CBD as a molecule or broad therapeutic use. It combines:
- A defined clinical population;
- A defined dose-escalation protocol;
- A defined CBD concentration;
- A defined impurity profile; and
- A defined oral formulation.
Its commercial relevance is higher than its apparent breadth because the limitations correspond closely to the FDA-approved Epidiolex product. Its vulnerability is also higher because each limitation must be proven. A challenge could target written description, enablement, obviousness, claim construction, anticipation, or the sufficiency of the impurity and clinical limitations.
Key Takeaways
- US 11,633,369 covers CBD seizure-treatment methods and an Epidiolex-type oral formulation.
- The nominal patent expiration date is June 30, 2037, subject to USPTO term adjustments and related-term records.
- Claims 1-28 require specified diseases, oral CBD administration, approximately 100 mg/mL CBD, impurity limits, and dose escalation.
- Claims 29-32 protect a formulation using CBD, sesame oil, ethanol, flavoring or sweetener, and tightly defined concentration ranges.
- The patent is relevant to generic ANDA applicants but not to biosimilar developers.
- The strongest infringement scenario is a 100 mg/mL CBD oral solution with Epidiolex-like excipients, impurity specifications, and labeling.
- Design-around opportunities exist through carrier oil, solvent, concentration, impurity profile, route, and labeling changes.
- Paragraph IV litigation and settlement conclusions require confirmation from Orange Book and federal court records.
FAQs
Does US 11,633,369 cover all cannabidiol products?
No. It covers defined treatment methods and a narrow oral formulation. CBD products outside the claimed diseases, concentrations, excipient system, dosing, or impurity profile may fall outside its literal scope.
Does the patent cover CBD for epilepsy outside Lennox-Gastaut and Dravet syndromes?
Claim 1 also recites tuberous sclerosis complex and Doose syndrome. The dependent claims further narrow those uses. Other epilepsy conditions are not expressly covered by the listed treatment claims.
Can a generic launch before June 30, 2037?
Potentially, but only if the generic sponsor defeats, avoids, licenses, or otherwise resolves applicable patents and regulatory exclusivity. Patent expiration alone does not determine launch eligibility.
Does a different flavor avoid the formulation claims?
A different flavor may avoid the narrower claims requiring the specified flavoring and sweetener concentrations, but claim 29 is broader and covers flavoring or sweetener. The full excipient and impurity profile must be assessed.
Is synthetic CBD automatically outside the patent?
No. The claims are directed to CBD drug substance and specified impurity limits, not expressly to plant-derived CBD. Synthetic CBD may still fall within the claims if the concentration, formulation, impurity, dosing, and indication limitations are met.
References
- U.S. Food and Drug Administration. (2023). Epidiolex (cannabidiol) oral solution prescribing information. FDA.
- U.S. Food and Drug Administration. (2020). FDA approves new indication for Epidiolex for seizures associated with tuberous sclerosis complex. FDA.
- United States Patent and Trademark Office. (2023). U.S. Patent No. 11,633,369. USPTO.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
- 21 U.S.C. § 355(j). Abbreviated new drug applications and patent certifications.